Document Detail


TRAIL and chemotherapeutic drugs in cancer therapy.
MedLine Citation:
PMID:  15110186     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL/Apo2L) is a recently identified member of the TNF ligand family that selectively induces apoptosis in tumor cells in vitro and in vivo but not in most normal cells. Chemotherapeutic drugs induce apoptosis and the upregulation of death receptors or activation of intracellular signaling pathways of TRAIL. Numerous chemotherapeutic drugs have been shown to sensitize tumor cells to TRAIL-mediated apoptosis. Studies from our laboratory have also shown that TRAIL-resistant renal cell carcinoma, prostate gland cancer, and bladder cancer cells are sensitized by subtoxic concentrations of chemotherapeutic drugs including doxorubicin, epirubicin, pirarubicin, and cisplatin. TRAIL, particularly in combination with chemotherapeutic agents, is thus potentially promising in the treatment of cancer. This review addresses the putative role of TRAIL in cancer treatment and discusses the molecular basis of the synergistic effect of TRAIL and chemotherapeutic drugs.
Authors:
Xiu-Xian Wu; Osamu Ogawa; Yoshiyuki Kakehi
Related Documents :
9264326 - Differential regulation of phospholipase a2 in human leukemia cells by the etherphospho...
15259086 - Effect of octreotide on human pancreatic cancer cells after transfected with somatostat...
25453956 - Multifunctional near infrared-emitting long-persistence luminescent nanoprobes for drug...
12697056 - Staphylococcus aureus - induced tumor necrosis factor - related apoptosis - inducing li...
21590006 - Analysis of the proliferative and phenotypic properties of tumor infiltrating lymphocyt...
19201456 - Organ-sparing microsurgical resection of incidental testicular tumors plus microdissect...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Vitamins and hormones     Volume:  67     ISSN:  0083-6729     ISO Abbreviation:  Vitam. Horm.     Publication Date:  2004  
Date Detail:
Created Date:  2004-04-27     Completed Date:  2004-07-07     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0413601     Medline TA:  Vitam Horm     Country:  United States    
Other Details:
Languages:  eng     Pagination:  365-83     Citation Subset:  IM    
Affiliation:
Department of Urology, Kagawa University, Kagawa 761-0793, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adaptor Proteins, Signal Transducing*
Animals
Antineoplastic Agents* / therapeutic use
Apoptosis
Apoptosis Regulatory Proteins
Carrier Proteins / metabolism
Caspase 8
Caspases / metabolism
Cytotoxicity, Immunologic
Drug Synergism
Fas-Associated Death Domain Protein
Humans
Membrane Glycoproteins* / physiology,  therapeutic use
Neoplasms / drug therapy*
Receptors, Tumor Necrosis Factor
Signal Transduction
TNF-Related Apoptosis-Inducing Ligand
Tumor Necrosis Factor-alpha* / physiology,  therapeutic use
Chemical
Reg. No./Substance:
0/Adaptor Proteins, Signal Transducing; 0/Antineoplastic Agents; 0/Apoptosis Regulatory Proteins; 0/Carrier Proteins; 0/FADD protein, human; 0/Fas-Associated Death Domain Protein; 0/Membrane Glycoproteins; 0/Receptors, Tumor Necrosis Factor; 0/TNF-Related Apoptosis-Inducing Ligand; 0/TNFSF10 protein, human; 0/Tumor Necrosis Factor-alpha; EC 3.4.22.-/CASP8 protein, human; EC 3.4.22.-/Caspase 8; EC 3.4.22.-/Caspases

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Potential for TRAIL as a therapeutic agent in ovarian cancer.
Next Document:  Additive effects of TRAIL and paclitaxel on cancer cells: implications for advances in cancer therap...